Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zeria Pharmaceutical Co's Enterprise Value is 円103,546 Mil.
Zeria Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Zeria Pharmaceutical Co's EV-to-FCF for today is .
The historical rank and industry rank for Zeria Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4559'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 14.46
Current: 14.46
During the past 13 years, the highest EV-to-FCF of Zeria Pharmaceutical Co was 14.46. The lowest was 0.00. And the median was 0.00.
TSE:4559's EV-to-FCF is ranked better than 64.49% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs TSE:4559: 14.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zeria Pharmaceutical Co (TSE:4559) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zeria Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Zeria Pharmaceutical Co's share price for today is 円2087.00.
Zeria Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円191.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zeria Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeria Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zeria Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zeria Pharmaceutical Co's EV-to-FCF falls into.
Zeria Pharmaceutical Co's current Enterprise Value is 円103,546 Mil.
Zeria Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Zeria Pharmaceutical Co (TSE:4559) Overvalued in 2026?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,087.00 is trading 16.7% below its estimated GF Value™ of 円2,506.68.
GuruFocus considers Zeria Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4559:
EV-to-FCF:
GF Value™: 円2,506.68 vs. price of 円2,087.00 (16.7% below fair value)
No single metric tells the full story. See the TSE:4559 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
85GF Score
Get the complete analysis for TSE:4559
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4559 has been successfully added to your 
